JP2015504847A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504847A5 JP2015504847A5 JP2014544946A JP2014544946A JP2015504847A5 JP 2015504847 A5 JP2015504847 A5 JP 2015504847A5 JP 2014544946 A JP2014544946 A JP 2014544946A JP 2014544946 A JP2014544946 A JP 2014544946A JP 2015504847 A5 JP2015504847 A5 JP 2015504847A5
- Authority
- JP
- Japan
- Prior art keywords
- mir
- cancer
- seq
- metastatic
- mirna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161565226P | 2011-11-30 | 2011-11-30 | |
| US61/565,226 | 2011-11-30 | ||
| PCT/US2012/067403 WO2013082499A1 (en) | 2011-11-30 | 2012-11-30 | Targeting micrornas mir-409-5p, mir-379 and mir-154* to treat prostate cancer bone metastasis and drug resistant lung cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015504847A JP2015504847A (ja) | 2015-02-16 |
| JP2015504847A5 true JP2015504847A5 (enExample) | 2016-01-14 |
Family
ID=48536124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014544946A Pending JP2015504847A (ja) | 2011-11-30 | 2012-11-30 | 前立腺癌骨転移および薬剤耐性肺癌を治療するためのマイクロｒｎａｍｉｒ−４０９−５ｐ、ｍｉｒ−３７９、およびｍｉｒ−１５４＊の標的化 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20140323551A1 (enExample) |
| EP (2) | EP2785355A4 (enExample) |
| JP (1) | JP2015504847A (enExample) |
| CN (1) | CN104080461A (enExample) |
| AU (1) | AU2012345666A1 (enExample) |
| WO (1) | WO2013082499A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9745578B2 (en) | 2011-11-30 | 2017-08-29 | Cedars-Sinai Medical Center | Targeting microRNA miR-409-3P to treat prostate cancer |
| BR112015016282A2 (en) * | 2013-01-07 | 2017-07-11 | Arog Pharmaceuticals, Inc. | crenolanib for treatment of mutated flt3 proliferative disorders |
| US10801071B2 (en) * | 2014-04-22 | 2020-10-13 | The Johns Hopkins University | TGF(β)-MIR200-MIG6 pathway and its use in the treatment of cancer as an indicator of resistance to EGFR inhibitors |
| EP3250706A4 (en) * | 2015-01-30 | 2018-09-05 | The Johns Hopkins University | Extracellular vesicles for agent delivery |
| US10870852B2 (en) | 2015-10-06 | 2020-12-22 | University Of Virginia Patent Foundation | Compositions and methods for treating diabetic retinopathy |
| US11878000B2 (en) * | 2016-10-21 | 2024-01-23 | Da Zen Theranostics, Inc. | Compounds and methods to sensitize cancer cells to tyrosine kinase inhibitors |
| US11584932B2 (en) | 2016-11-01 | 2023-02-21 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
| US11236337B2 (en) | 2016-11-01 | 2022-02-01 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
| CN110291089B (zh) | 2017-01-17 | 2022-05-27 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂 |
| JP7164939B2 (ja) | 2017-08-25 | 2022-11-02 | 株式会社サムスン日本研究所 | 全固体型二次電池 |
| US10854877B2 (en) | 2017-08-25 | 2020-12-01 | Samsung Electronics Co., Ltd. | All-solid-state secondary battery |
| CN107488734B (zh) * | 2017-10-10 | 2019-11-05 | 广州医科大学附属第二医院 | miR-19a-3p在制备前列腺癌骨转移诊断试剂和治疗药物中的应用 |
| CN107630092B (zh) * | 2017-10-23 | 2020-03-31 | 广州医科大学附属第二医院 | miR-505-3p应用于前列腺癌骨转移的诊断、预后和治疗 |
| CN108148911B (zh) * | 2018-03-02 | 2019-11-05 | 广州医科大学附属第二医院 | miR-582在制备前列腺癌骨转移的诊断、预后试剂盒及药物中的应用 |
| KR102132222B1 (ko) * | 2018-11-27 | 2020-07-09 | 강원대학교산학협력단 | 항암제 내성 진단 마커로서의 miR-143-3p 및 miR-373-5p, 및 이의 이용 |
| CN110305863B (zh) * | 2019-06-10 | 2020-12-08 | 浙江大学 | 用于上调人DLK1-DIO3印记域非编码RNA表达的sgRNA、重组质粒和细胞株 |
| CN110819718B (zh) * | 2019-12-16 | 2023-05-26 | 广州医科大学附属第二医院 | miR-154-5p在前列腺癌骨转移的新应用 |
| CN115768780A (zh) * | 2020-04-07 | 2023-03-07 | 领先细胞医疗诊断有限公司 | 通过原位杂交检测靶核酸的方法及其试剂盒 |
| WO2021262919A2 (en) | 2020-06-26 | 2021-12-30 | The Research Foundation For The State University Of New York | 5-halouracil-modified micrornas and their use in the treatment of cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005111211A2 (en) * | 2004-05-14 | 2005-11-24 | Rosetta Genomics Ltd. | Micronas and uses thereof |
| CA2857878A1 (en) * | 2004-11-12 | 2006-12-28 | Asuragen, Inc. | Methods and compositions involving mirna and mirna inhibitor molecules |
| US20060265771A1 (en) * | 2005-05-17 | 2006-11-23 | Lewis David L | Monitoring microrna expression and function |
| US20070065844A1 (en) * | 2005-06-08 | 2007-03-22 | Massachusetts Institute Of Technology | Solution-based methods for RNA expression profiling |
| CN103820562B (zh) * | 2005-08-01 | 2015-05-13 | 俄亥俄州立大学研究基金会 | 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物 |
| CN101622348A (zh) * | 2006-12-08 | 2010-01-06 | 奥斯瑞根公司 | 作为治疗性干预靶标的miR-20调节的基因和途径 |
| WO2008109105A2 (en) * | 2007-03-06 | 2008-09-12 | Flagship Ventures | Methods and compositions for improved therapeutic effects with sirna |
| ES2463665T3 (es) * | 2007-10-04 | 2014-05-28 | Stella Aps | Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C |
| US20110054009A1 (en) * | 2008-02-28 | 2011-03-03 | The Ohio State University Research Foundation | MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Prostate Related Disorders |
| US20100179213A1 (en) * | 2008-11-11 | 2010-07-15 | Mirna Therapeutics, Inc. | Methods and Compositions Involving miRNAs In Cancer Stem Cells |
| WO2010135692A2 (en) * | 2009-05-22 | 2010-11-25 | Asuragen, Inc. | Mirna biomarkers of prostate disease |
| CN102080085B (zh) * | 2009-12-01 | 2013-01-16 | 中国科学院上海药物研究所 | 人miR-193b反义核酸及其应用 |
| WO2011076142A1 (en) * | 2009-12-24 | 2011-06-30 | Fudan University | Compositions and methods for microrna expession profiling in plasma of colorectal cancer |
-
2012
- 2012-11-30 WO PCT/US2012/067403 patent/WO2013082499A1/en not_active Ceased
- 2012-11-30 CN CN201280067969.XA patent/CN104080461A/zh active Pending
- 2012-11-30 AU AU2012345666A patent/AU2012345666A1/en not_active Abandoned
- 2012-11-30 EP EP12854115.8A patent/EP2785355A4/en not_active Withdrawn
- 2012-11-30 US US14/360,489 patent/US20140323551A1/en not_active Abandoned
- 2012-11-30 EP EP16170595.9A patent/EP3106168A3/en not_active Withdrawn
- 2012-11-30 JP JP2014544946A patent/JP2015504847A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Porru et al. | Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities | |
| Deschênes-Simard et al. | ERKs in cancer: friends or foes? | |
| Zhang et al. | miR-221/222 promote malignant progression of glioma through activation of the Akt pathway Expression of Concern in/10.3892/ijo. 2025.5808 | |
| RU2017125053A (ru) | Терапевтические, диагностические и прогностические способы для рака мочевого пузыря | |
| Pop et al. | Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib | |
| Barciszewska | MicroRNAs as efficient biomarkers in high-grade gliomas | |
| JP2016536303A5 (enExample) | ||
| US10214743B2 (en) | Colorectal cancer drug, and method for predicting prognosis of colorectal cancer patient | |
| Jing et al. | Down-expression of miR-373 predicts poor prognosis of glioma and could be a potential therapeutic target | |
| Rehman et al. | 14-3-3ζ Orchestrates Mammary Tumor Onset and Progression via miR-221–Mediated Cell Proliferation | |
| Gardini et al. | Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group | |
| Yu et al. | Knockdown of long non-coding RNA LCPAT1 inhibits autophagy in lung cancer | |
| G. Leon et al. | Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells | |
| AU2018422285B2 (en) | Determining cancer responsiveness to treatment | |
| Li et al. | Low levels of serum miR-99a is a predictor of poor prognosis in breast cancer | |
| Ding et al. | Knockdown of ras-related protein 25 (Rab25) inhibits the in vitro cytotoxicity and in vivo antitumor activity of human glioblastoma multiforme cells | |
| Agliano et al. | Pediatric and adult glioblastoma radiosensitization induced by PI3K/mTOR inhibition causes early metabolic alterations detected by nuclear magnetic resonance spectroscopy | |
| Liao et al. | Yiqi Formula Enhances the Antitumor Effects of Erlotinib for Treatment of Triple‐Negative Breast Cancer Xenografts | |
| EP2204177B1 (en) | Cancer marker and therapeutic agent for cancer | |
| Kastler et al. | P10. 08. A Lipogenesis inhibition by fatostatin shows effectiveness in glioblastoma models highly expressing fatty acid synthase (FASN) | |
| Tsiani | P1. 03-03 Inhibition of H1299 Lung cancer cell proliferation and survival by rosemary extract Is associated with AMPK activation | |
| Wang et al. | The prevalence and prognostic significance of JAK2 mutation subtypes in non-small cell lung cancer from Chinese populations | |
| Zhuo et al. | Sufentanil Inhibits Proliferation, Migration, and Invasion of Hepatocellular Carcinoma Cells by Upregulating miRNA-204 | |
| Fishman et al. | P10. 10. A Tumor Treating Fields (TTFields), temozolomide and lomustine co-application is efficacious in glioblastoma cancer cell lines | |
| De Jonge et al. | 396 A Phase I, Dose-finding Study of BI 853520, a Potent and Selective Inhibitor of Protein Tyrosine Kinase 2 in Patients with Advanced or Metastatic Solid Tumors |